PCM-16MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS
نویسندگان
چکیده
منابع مشابه
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma †
Metastatic melanoma is a recalcitrant tumor. Although "targeted" and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to i...
متن کاملPatient-derived xenograft (PDX) tumors increase growth rate with time
Patient-derived xenograft (PDX) models are frequently used for translational cancer research, and are assumed to behave consistently as the tumor ages. However, growth rate constancy as a function of time is unclear. Notably, variable PDX growth rates over time might have implications for the interpretation of translational studies. We characterized four PDX models through several in vivo passa...
متن کاملGenomic Profiling of Patient-Derived Colon Cancer Xenograft Models
Recent evidence suggests that patient derived xenograft (PDX) models can maintain certain pathological and molecular features of the original disease. However, these characterizations are limited to immunohistochemistry or by tissue microarray analysis. We conducted a high-throughput sequencing of primary colon tumor and PDX has not been reported yet. Fresh primary colon cancer tissues that ori...
متن کاملNext generation patient-derived prostate cancer xenograft models
leading cause of cancer-related death of North American males.1 The disease is at present incurable once it has metastasized, and most deaths from this disease are due to metastases that are highly resistant to current conventional therapies. Prostate cancer is considered a multifocal disease that generally consists of a dominant cancer and one or more concurrent cancers of smaller volume with ...
متن کاملPatient-derived xenograft models for oncology drug discovery
The success of targeted therapies for cancer patients rests on three major components: the right target(s), the right drug and drug combination, and the right patient population. Although much progress has been made in understanding the mechanism of disease and in refi ning pharmaceutical properties of therapeutic agents, the attrition rates between target discovery and drug marketing approval ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2016
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/now080.16